- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Artifact Reduction Drives Technology Advances with Updated Version of Echelon Synergy MRI System
Emerging technologies included with the 10th version of the 1.5T MRI platform include Synergy DLR Clear and Synergy Vision that are geared toward mitigating common challenges with artifacts.
Fujifilm Healthcare has made artifact reduction a key focus of advances with the newly launched 10th version of the Echelon Synergy 1.5T magnetic resonance imaging (MRI) system.
Offering multiple in-bore cameras and the use of real-time tracking from scans to correct motion-compromised raw data, the updated Echelon Synergy device’s combination of Synergy Vision and StillShot artificial intelligence (AI) mitigates motion artifacts, according to Fujifilm Healthcare.
Mitigating artifacts is a key driver of new technological advances included in version 10 of the Echelon Synergy 1.5T MRI system. (Image courtesy of Fujifilm Healthcare.)
The company added that the Echelon Synergy’s inclusion of the AI-powered algorithm DLR Clear addresses the challenging truncation artifact without the need for extended scan time.
“With the v10 (Echelon Synergy), technologists can now apply our RADAR radial sequence with our iterative iRCM IP-Recon processing to mitigate spike artifacts, resulting in clear, high-quality images with reduced motion artifact,” noted Shawn Etheridge, the executive director of modality solutions for Fujifilm Healthcare Americas Corporation.
Fujifilm noted that the upgraded standard software features with version 10 of the Echelon Synergy 1.5T MRI will be provided to current customers free of charge.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
